{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:17:02Z","timestamp":1791487022193,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"crossref","award":["201906170053"],"award-info":[{"award-number":["201906170053"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Conditions such as hyperglycemia and oxidative stress lead to the formation of advanced glycation end products (AGEs), which are harmful compounds that have been implicated in dementia. Within the Rotterdam Study, we measured skin AGEs as skin autofluorescence, reflecting long-term accumulation of AGEs, and determined their association with the risk of dementia and with brain magnetic resonance imaging (MRI) measures. Skin autofluorescence was measured between 2013 and 2016 in 2922 participants without dementia. Of these, 1504 also underwent brain MRI, on which measures of brain atrophy and cerebral small vessel disease were assessed. All participants were followed for the incidence of dementia until 2020. Of 2922 participants (mean age 72.6\u00a0years, 57% women), 123 developed dementia. Higher skin autofluorescence (per standard deviation) was associated with an increased risk of dementia (hazard ratio 1.21 [95% confidence interval 1.01\u20131.46]) and Alzheimer\u2019s disease (1.19 [0.97\u20131.47]), independently of age and other studied potential confounders. Stronger effects were seen in apolipoprotein E (<jats:italic>APOE)<\/jats:italic> \u03b54 carriers (1.34 [0.98\u20131.82]) and in participants with diabetes (1.35 [0.94\u20131.94]). Participants with higher skin autofluorescence levels also had smaller total brain volumes and smaller hippocampus volumes on MRI, and they had more often lacunes. These results suggest that AGEs may be involved in dementia pathophysiology.<\/jats:p>","DOI":"10.1038\/s41598-024-51703-6","type":"journal-article","created":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T11:02:24Z","timestamp":1705143744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Skin autofluorescence, reflecting accumulation of advanced glycation end products, and the risk of dementia in a population-based cohort"],"prefix":"10.1038","volume":"14","author":[{"given":"Sanne S.","family":"Mooldijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Waqas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinluan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike W.","family":"Vernooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Kamran","family":"Ikram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Carola","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0372-8585","authenticated-orcid":false,"given":"M. Arfan","family":"Ikram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,13]]},"reference":[{"key":"51703_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s001250051591","volume":"44","author":"R Singh","year":"2001","unstructured":"Singh, R., Barden, A., Mori, T. & Beilin, L. Advanced glycation end-products: A review. Diabetologia 44, 129\u2013146. https:\/\/doi.org\/10.1007\/s001250051591 (2001).","journal-title":"Diabetologia"},{"key":"51703_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev.med.46.1.223","volume":"46","author":"M Brownlee","year":"1995","unstructured":"Brownlee, M. Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med. 46, 223\u2013234. https:\/\/doi.org\/10.1146\/annurev.med.46.1.223 (1995).","journal-title":"Annu. Rev. Med."},{"key":"51703_CR3","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s00109-005-0688-7","volume":"83","author":"A Bierhaus","year":"2005","unstructured":"Bierhaus, A. et al. Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. (Berl.) 83, 876\u2013886. https:\/\/doi.org\/10.1007\/s00109-005-0688-7 (2005).","journal-title":"J. Mol. Med. (Berl.)"},{"key":"51703_CR4","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1212\/WNL.0b013e3182315a56","volume":"77","author":"K Yaffe","year":"2011","unstructured":"Yaffe, K. et al. Advanced glycation end product level, diabetes, and accelerated cognitive aging. Neurology 77, 1351\u20131356. https:\/\/doi.org\/10.1212\/WNL.0b013e3182315a56 (2011).","journal-title":"Neurology"},{"key":"51703_CR5","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.neurobiolaging.2009.04.016","volume":"32","author":"V Srikanth","year":"2011","unstructured":"Srikanth, V. et al. Advanced glycation endproducts and their receptor RAGE in Alzheimer\u2019s disease. Neurobiol. Aging 32, 763\u2013777. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2009.04.016 (2011).","journal-title":"Neurobiol. Aging"},{"key":"51703_CR6","doi-asserted-by":"publisher","first-page":"973","DOI":"10.2174\/138161208784139693","volume":"14","author":"M Takeuchi","year":"2008","unstructured":"Takeuchi, M. & Yamagishi, S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer\u2019s disease. Curr. Pharm. Des. 14, 973\u2013978. https:\/\/doi.org\/10.2174\/138161208784139693 (2008).","journal-title":"Curr. Pharm. Des."},{"key":"51703_CR7","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.3233\/JAD-160917","volume":"55","author":"M Igase","year":"2017","unstructured":"Igase, M. et al. Skin autofluorescence examination as a diagnostic tool for mild cognitive impairment in healthy people. J. Alzheimers Dis. 55, 1481\u20131487. https:\/\/doi.org\/10.3233\/JAD-160917 (2017).","journal-title":"J. Alzheimers Dis."},{"key":"51703_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2337\/db14-0506","volume":"64","author":"C Moran","year":"2015","unstructured":"Moran, C. et al. Type 2 diabetes, skin autofluorescence, and brain atrophy. Diabetes 64, 279\u2013283. https:\/\/doi.org\/10.2337\/db14-0506 (2015).","journal-title":"Diabetes"},{"key":"51703_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/gerona\/gls100","volume":"68","author":"V Srikanth","year":"2013","unstructured":"Srikanth, V. et al. Methylglyoxal, cognitive function and cerebral atrophy in older people. J. Gerontol. A Biol. Sci. Med. Sci. 68, 68\u201373. https:\/\/doi.org\/10.1093\/gerona\/gls100 (2013).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"51703_CR10","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0002-9440(10)65659-3","volume":"153","author":"N Sasaki","year":"1998","unstructured":"Sasaki, N. et al. Advanced glycation end products in Alzheimer\u2019s disease and other neurodegenerative diseases. Am. J. Pathol. 153, 1149\u20131155. https:\/\/doi.org\/10.1016\/S0002-9440(10)65659-3 (1998).","journal-title":"Am. J. Pathol."},{"key":"51703_CR11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/nm890","volume":"9","author":"R Deane","year":"2003","unstructured":"Deane, R. et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9, 907\u2013913. https:\/\/doi.org\/10.1038\/nm890 (2003).","journal-title":"Nat. Med."},{"key":"51703_CR12","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1093\/jnen\/nlaa064","volume":"79","author":"A Chambers","year":"2020","unstructured":"Chambers, A. et al. Advanced glycation end product formation in human cerebral cortex increases with Alzheimer-type neuropathologic changes but is not independently associated with dementia in a population-derived aging brain cohort. J. Neuropathol. Exp. Neurol. 79, 950\u2013958. https:\/\/doi.org\/10.1093\/jnen\/nlaa064 (2020).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"51703_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3233\/jad-2002-4203","volume":"4","author":"M Meli","year":"2002","unstructured":"Meli, M. et al. Serum pentosidine as an indicator of Alzheimer\u2019s disease. J. Alzheimers Dis. 4, 93\u201396. https:\/\/doi.org\/10.3233\/jad-2002-4203 (2002).","journal-title":"J. Alzheimers Dis."},{"key":"51703_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/cercor\/bhh123","volume":"15","author":"H-J L\u00fcth","year":"2004","unstructured":"L\u00fcth, H.-J. et al. Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer\u2019s disease brains. Cereb. Cortex 15, 211\u2013220. https:\/\/doi.org\/10.1093\/cercor\/bhh123 (2004).","journal-title":"Cereb. Cortex"},{"key":"51703_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/s0197-4580(02)00086-6","volume":"24","author":"KJ B\u00e4r","year":"2003","unstructured":"B\u00e4r, K. J. et al. Pentosidine and N(epsilon)-(carboxymethyl)-lysine in Alzheimer\u2019s disease and vascular dementia. Neurobiol. Aging 24, 333\u2013338. https:\/\/doi.org\/10.1016\/s0197-4580(02)00086-6 (2003).","journal-title":"Neurobiol. Aging"},{"key":"51703_CR16","doi-asserted-by":"publisher","first-page":"576","DOI":"10.4158\/1934-2403-26.5.576","volume":"26","author":"MS Beeri","year":"2020","unstructured":"Beeri, M. S., Uribarri, J., Cai, W., Buchman, A. S. & Haroutunian, V. Human brain and serum advanced glycation end products are highly correlated: Preliminary results of their role in Alzheimer disease and type 2 diabetes. Endocr. Pract. 26, 576\u2013577. https:\/\/doi.org\/10.4158\/1934-2403-26.5.576 (2020).","journal-title":"Endocr. Pract."},{"key":"51703_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1471-4159.2004.02864.x","volume":"92","author":"N Ahmed","year":"2005","unstructured":"Ahmed, N. et al. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer\u2019s disease and link to cognitive impairment. J. Neurochem. 92, 255\u2013263. https:\/\/doi.org\/10.1111\/j.1471-4159.2004.02864.x (2005).","journal-title":"J. Neurochem."},{"key":"51703_CR18","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1073\/pnas.1402277111","volume":"111","author":"S Lovestone","year":"2014","unstructured":"Lovestone, S. & Smith, U. Advanced glycation end products, dementia, and diabetes. Proc. Natl. Acad. Sci. USA 111, 4743\u20134744. https:\/\/doi.org\/10.1073\/pnas.1402277111 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"51703_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.33012","volume":"4","author":"J Chen","year":"2021","unstructured":"Chen, J. et al. Assessment of advanced glycation end products and receptors and the risk of dementia. JAMA Netw. Open 4, e2033012. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.33012 (2021).","journal-title":"JAMA Netw. Open"},{"key":"51703_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/s0304-3940(97)00266-8","volume":"226","author":"YM Li","year":"1997","unstructured":"Li, Y. M. & Dickson, D. W. Enhanced binding of advanced glycation endproducts (AGE) by the ApoE4 isoform links the mechanism of plaque deposition in Alzheimer\u2019s disease. Neurosci. Lett. 226, 155\u2013158. https:\/\/doi.org\/10.1016\/s0304-3940(97)00266-8 (1997).","journal-title":"Neurosci. Lett."},{"key":"51703_CR21","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s00125-004-1451-2","volume":"47","author":"R Meerwaldt","year":"2004","unstructured":"Meerwaldt, R. et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 47, 1324\u20131330. https:\/\/doi.org\/10.1007\/s00125-004-1451-2 (2004).","journal-title":"Diabetologia"},{"key":"51703_CR22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00125-018-4769-x","volume":"62","author":"RP van Waateringe","year":"2019","unstructured":"van Waateringe, R. P. et al. Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease and mortality in the general population. Diabetologia 62, 269\u2013280. https:\/\/doi.org\/10.1007\/s00125-018-4769-x (2019).","journal-title":"Diabetologia"},{"key":"51703_CR23","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1210\/jc.2014-2754","volume":"100","author":"PJJ Spauwen","year":"2015","unstructured":"Spauwen, P. J. J. et al. Associations of advanced glycation end-products with cognitive functions in individuals with and without type 2 diabetes: The Maastricht Study. J. Clin. Endocrinol. Metab. 100, 951\u2013960. https:\/\/doi.org\/10.1210\/jc.2014-2754 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"51703_CR24","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10654-020-00640-5","volume":"35","author":"MA Ikram","year":"2020","unstructured":"Ikram, M. A. et al. Objectives, design and main findings until 2020 from the Rotterdam Study. Eur. J. Epidemiol. 35, 483\u2013517. https:\/\/doi.org\/10.1007\/s10654-020-00640-5 (2020).","journal-title":"Eur. J. Epidemiol."},{"key":"51703_CR25","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s10654-015-0105-7","volume":"30","author":"MA Ikram","year":"2015","unstructured":"Ikram, M. A. et al. The Rotterdam Scan Study: Design update 2016 and main findings. Eur. J. Epidemiol. 30, 1299\u20131315. https:\/\/doi.org\/10.1007\/s10654-015-0105-7 (2015).","journal-title":"Eur. J. Epidemiol."},{"key":"51703_CR26","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.neuroimage.2004.07.016","volume":"23","author":"B Fischl","year":"2004","unstructured":"Fischl, B. et al. Sequence-independent segmentation of magnetic resonance images. NeuroImage 23, S69\u2013S84. https:\/\/doi.org\/10.1016\/j.neuroimage.2004.07.016 (2004).","journal-title":"NeuroImage"},{"key":"51703_CR27","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604\u2013612. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006 (2009).","journal-title":"Ann. Intern. Med."},{"key":"51703_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/978-1-4939-0446-4_6","volume":"1145","author":"J Woodward","year":"2014","unstructured":"Woodward, J. Bi-allelic SNP genotyping using the TaqMan\u00ae assay. Methods Mol. Biol. 1145, 67\u201374. https:\/\/doi.org\/10.1007\/978-1-4939-0446-4_6 (2014).","journal-title":"Methods Mol. Biol."},{"key":"51703_CR29","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/0140-6736(91)92823-k","volume":"337","author":"PR Wenham","year":"1991","unstructured":"Wenham, P. R., Price, W. H. & Blandell, G. Apolipoprotein E genotyping by one-stage PCR. Lancet 337, 1158\u20131159. https:\/\/doi.org\/10.1016\/0140-6736(91)92823-k (1991).","journal-title":"Lancet"},{"key":"51703_CR30","doi-asserted-by":"publisher","first-page":"4766","DOI":"10.1073\/pnas.91.11.4766","volume":"91","author":"MP Vitek","year":"1994","unstructured":"Vitek, M. P. et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. USA 91, 4766\u20134770. https:\/\/doi.org\/10.1073\/pnas.91.11.4766 (1994).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"51703_CR31","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.1073\/pnas.91.12.5710","volume":"91","author":"MA Smith","year":"1994","unstructured":"Smith, M. A. et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl. Acad. Sci. USA 91, 5710\u20135714. https:\/\/doi.org\/10.1073\/pnas.91.12.5710 (1994).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"51703_CR32","doi-asserted-by":"publisher","first-page":"7787","DOI":"10.1073\/pnas.91.16.7787","volume":"91","author":"SD Yan","year":"1994","unstructured":"Yan, S. D. et al. Glycated tau protein in Alzheimer disease: A mechanism for induction of oxidant stress. Proc. Natl. Acad. Sci. USA 91, 7787\u20137791. https:\/\/doi.org\/10.1073\/pnas.91.16.7787 (1994).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"51703_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.nbd.2009.09.008","volume":"37","author":"T Valente","year":"2010","unstructured":"Valente, T., Gella, A., Fern\u00e0ndez-Busquets, X., Unzeta, M. & Durany, N. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer\u2019s disease and diabetes mellitus. Neurobiol. Dis. 37, 67\u201376. https:\/\/doi.org\/10.1016\/j.nbd.2009.09.008 (2010).","journal-title":"Neurobiol. Dis."},{"key":"51703_CR34","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00726-010-0777-y","volume":"42","author":"G M\u00fcnch","year":"2012","unstructured":"M\u00fcnch, G., Westcott, B., Menini, T. & Gugliucci, A. Advanced glycation endproducts and their pathogenic roles in neurological disorders. Amino Acids 42, 1221\u20131236. https:\/\/doi.org\/10.1007\/s00726-010-0777-y (2012).","journal-title":"Amino Acids"},{"key":"51703_CR35","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10571-015-0233-3","volume":"36","author":"Z Cai","year":"2016","unstructured":"Cai, Z. et al. Role of RAGE in Alzheimer\u2019s disease. Cell. Mol. Neurobiol. 36, 483\u2013495. https:\/\/doi.org\/10.1007\/s10571-015-0233-3 (2016).","journal-title":"Cell. Mol. Neurobiol."},{"key":"51703_CR36","doi-asserted-by":"publisher","first-page":"8845","DOI":"10.1523\/JNEUROSCI.6102-11.2012","volume":"32","author":"S-Y Kook","year":"2012","unstructured":"Kook, S.-Y. et al. A\u03b21\u201342-RAGE interaction disrupts tight junctions of the blood\u2013brain barrier via Ca2+-calcineurin signaling. J. Neurosci. 32, 8845\u20138854. https:\/\/doi.org\/10.1523\/JNEUROSCI.6102-11.2012 (2012).","journal-title":"J. Neurosci."},{"key":"51703_CR37","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1172\/jci58642","volume":"122","author":"R Deane","year":"2012","unstructured":"Deane, R. et al. A multimodal RAGE-specific inhibitor reduces amyloid \u03b2-mediated brain disorder in a mouse model of Alzheimer disease. J. Clin. Investig. 122, 1377\u20131392. https:\/\/doi.org\/10.1172\/jci58642 (2012).","journal-title":"J. Clin. Investig."},{"key":"51703_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108304","volume":"180","author":"Y-Y Huang","year":"2020","unstructured":"Huang, Y.-Y. et al. RP1, a RAGE antagonist peptide, can improve memory impairment and reduce A\u03b2 plaque load in the APP\/PS1 mouse model of Alzheimer\u2019s disease. Neuropharmacology 180, 108304. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108304 (2020).","journal-title":"Neuropharmacology"},{"key":"51703_CR39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.neuropharm.2014.09.019","volume":"89","author":"C Lv","year":"2015","unstructured":"Lv, C. et al. Multi-faced neuroprotective effects of geniposide depending on the RAGE-mediated signaling in an Alzheimer mouse model. Neuropharmacology 89, 175\u2013184. https:\/\/doi.org\/10.1016\/j.neuropharm.2014.09.019 (2015).","journal-title":"Neuropharmacology"},{"key":"51703_CR40","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s12035-016-9783-8","volume":"54","author":"L Cui","year":"2017","unstructured":"Cui, L. et al. A novel, multi-target natural drug candidate, matrine, improves cognitive deficits in Alzheimer\u2019s disease transgenic mice by inhibiting A\u03b2 aggregation and blocking the RAGE\/A\u03b2 axis. Mol. Neurobiol. 54, 1939\u20131952. https:\/\/doi.org\/10.1007\/s12035-016-9783-8 (2017).","journal-title":"Mol. Neurobiol."},{"key":"51703_CR41","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1212\/wnl.0000000000000364","volume":"82","author":"D Galasko","year":"2014","unstructured":"Galasko, D. et al. Clinical trial of an inhibitor of RAGE-A\u03b2 interactions in Alzheimer disease. Neurology 82, 1536\u20131542. https:\/\/doi.org\/10.1212\/wnl.0000000000000364 (2014).","journal-title":"Neurology"},{"key":"51703_CR42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.14283\/jpad.2018.18","volume":"5","author":"AH Burstein","year":"2018","unstructured":"Burstein, A. H. et al. Development of azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer\u2019s disease. J. Prev. Alzheimer\u2019s Dis. 5, 149\u2013154. https:\/\/doi.org\/10.14283\/jpad.2018.18 (2018).","journal-title":"J. Prev. Alzheimer's Dis."},{"key":"51703_CR43","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"C-C Liu","year":"2013","unstructured":"Liu, C.-C., Liu, C.-C., Kanekiyo, T., Xu, H. & Bu, G. Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat. Rev. Neurol. 9, 106\u2013118. https:\/\/doi.org\/10.1038\/nrneurol.2012.263 (2013).","journal-title":"Nat. Rev. Neurol."},{"key":"51703_CR44","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.2337\/diabetes.51.4.1256","volume":"51","author":"R Peila","year":"2002","unstructured":"Peila, R., Rodriguez, B. L. & Launer, L. J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51, 1256\u20131262. https:\/\/doi.org\/10.2337\/diabetes.51.4.1256 (2002).","journal-title":"Diabetes"},{"key":"51703_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2019.100944","volume":"55","author":"M Xue","year":"2019","unstructured":"Xue, M. et al. Diabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 144 prospective studies. Ageing Res. Rev. 55, 100944. https:\/\/doi.org\/10.1016\/j.arr.2019.100944 (2019).","journal-title":"Ageing Res. Rev."},{"key":"51703_CR46","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/biom5010194","volume":"5","author":"K Nowotny","year":"2015","unstructured":"Nowotny, K., Jung, T., H\u00f6hn, A., Weber, D. & Grune, T. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules 5, 194\u2013222. https:\/\/doi.org\/10.3390\/biom5010194 (2015).","journal-title":"Biomolecules"},{"key":"51703_CR47","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/gerona\/glu243","volume":"70","author":"K Rajaobelina","year":"2015","unstructured":"Rajaobelina, K. et al. Autofluorescence of skin advanced glycation end products: Marker of metabolic memory in elderly population. J. Gerontol. Ser. A 70, 841\u2013846. https:\/\/doi.org\/10.1093\/gerona\/glu243 (2015).","journal-title":"J. Gerontol. Ser. A"},{"key":"51703_CR48","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cell.2005.04.028","volume":"122","author":"KL Spalding","year":"2005","unstructured":"Spalding, K. L., Bhardwaj, R. D., Buchholz, B. A., Druid, H. & Fris\u00e9n, J. Retrospective birth dating of cells in humans. Cell 122, 133\u2013143. https:\/\/doi.org\/10.1016\/j.cell.2005.04.028 (2005).","journal-title":"Cell"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51703-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51703-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51703-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T11:03:26Z","timestamp":1705143806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51703-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,13]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51703"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-51703-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,13]]},"assertion":[{"value":"21 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1256"}}